Sanara MedTech Inc. (SMTI)
USD 31.79
(-6.47%)
USD 31.79
(-6.47%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 64.98 Million USD | 41.77% |
| 2022 | 45.84 Million USD | 89.87% |
| 2021 | 24.14 Million USD | 54.9% |
| 2020 | 15.58 Million USD | 32.47% |
| 2019 | 11.76 Million USD | 101.56% |
| 2018 | 5.83 Million USD | -7.41% |
| 2017 | 6.3 Million USD | 14.47% |
| 2016 | 5.5 Million USD | 63.33% |
| 2015 | 3.37 Million USD | 28.09% |
| 2014 | 2.63 Million USD | 52.49% |
| 2013 | 1.72 Million USD | 47.11% |
| 2012 | 1.17 Million USD | -46.89% |
| 2011 | 2.2 Million USD | 142.71% |
| 2010 | 910.42 Thousand USD | 216.1% |
| 2009 | 288.02 Thousand USD | -0.75% |
| 2008 | 290.18 Thousand USD | -53.98% |
| 2007 | 630.5 Thousand USD | 232.27% |
| 2006 | 189.75 Thousand USD | -10.14% |
| 2005 | 211.16 Thousand USD | 148.38% |
| 2004 | 85.01 Thousand USD | 0.0% |
| 2001 | 20.95 Thousand USD | -99.09% |
| 2000 | 2.3 Million USD | 2.41% |
| 1999 | 2.25 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 18.53 Million USD | 4.79% |
| 2024 Q2 | 20.15 Million USD | 8.75% |
| 2023 Q3 | 16.02 Million USD | 1.73% |
| 2023 Q4 | 17.68 Million USD | 10.39% |
| 2023 FY | 64.98 Million USD | 41.77% |
| 2023 Q2 | 15.75 Million USD | 1.49% |
| 2023 Q1 | 15.52 Million USD | 1.34% |
| 2022 Q1 | 7.81 Million USD | 11.06% |
| 2022 Q2 | 9.67 Million USD | 23.81% |
| 2022 Q4 | 15.31 Million USD | 17.41% |
| 2022 Q3 | 13.04 Million USD | 34.89% |
| 2022 FY | 45.84 Million USD | 89.87% |
| 2021 Q2 | 6.27 Million USD | 25.31% |
| 2021 FY | 24.14 Million USD | 54.9% |
| 2021 Q3 | 5.82 Million USD | -7.22% |
| 2021 Q4 | 7.03 Million USD | 20.77% |
| 2021 Q1 | 5 Million USD | 4.6% |
| 2020 Q3 | 4.3 Million USD | 45.13% |
| 2020 Q2 | 2.96 Million USD | -15.81% |
| 2020 Q4 | 4.78 Million USD | 11.21% |
| 2020 FY | 15.58 Million USD | 32.47% |
| 2020 Q1 | 3.52 Million USD | 5.11% |
| 2019 Q2 | 3.01 Million USD | 21.34% |
| 2019 FY | 11.76 Million USD | 101.56% |
| 2019 Q4 | 3.35 Million USD | 15.26% |
| 2019 Q3 | 2.9 Million USD | -3.59% |
| 2019 Q1 | 2.48 Million USD | 5131.5% |
| 2018 Q3 | 1.56 Million USD | -30.75% |
| 2018 Q2 | 2.26 Million USD | 15.31% |
| 2018 Q1 | 1.96 Million USD | 15.56% |
| 2018 FY | 5.83 Million USD | -7.41% |
| 2018 Q4 | 47.53 Thousand USD | -96.97% |
| 2017 Q4 | 1.69 Million USD | 9.59% |
| 2017 Q1 | 1.6 Million USD | -8.02% |
| 2017 Q3 | 1.54 Million USD | 6.62% |
| 2017 Q2 | 1.45 Million USD | -9.49% |
| 2017 FY | 6.3 Million USD | 14.47% |
| 2016 Q3 | 1.4 Million USD | 12.05% |
| 2016 Q1 | 1.09 Million USD | 54.81% |
| 2016 Q2 | 1.25 Million USD | 14.86% |
| 2016 FY | 5.5 Million USD | 63.33% |
| 2016 Q4 | 1.74 Million USD | 23.81% |
| 2015 Q2 | 745.11 Thousand USD | -26.52% |
| 2015 Q3 | 905.61 Thousand USD | 21.54% |
| 2015 FY | 3.37 Million USD | 28.09% |
| 2015 Q1 | 1.01 Million USD | 39.5% |
| 2015 Q4 | 707.46 Thousand USD | -21.88% |
| 2014 Q4 | 726.87 Thousand USD | 7.03% |
| 2014 Q3 | 679.12 Thousand USD | 24.76% |
| 2014 Q2 | 544.35 Thousand USD | -20.22% |
| 2014 Q1 | 682.29 Thousand USD | 47.29% |
| 2014 FY | 2.63 Million USD | 52.49% |
| 2013 Q3 | 472.75 Thousand USD | 13.73% |
| 2013 Q2 | 415.69 Thousand USD | 10.93% |
| 2013 Q1 | 374.72 Thousand USD | -14.71% |
| 2013 FY | 1.72 Million USD | 47.11% |
| 2013 Q4 | 463.22 Thousand USD | -2.02% |
| 2012 FY | 1.17 Million USD | -46.89% |
| 2012 Q4 | 439.35 Thousand USD | 21.96% |
| 2012 Q3 | 360.24 Thousand USD | 33.52% |
| 2012 Q2 | 269.81 Thousand USD | 159.1% |
| 2012 Q1 | 104.13 Thousand USD | -88.59% |
| 2011 Q1 | 935.41 Thousand USD | 51.41% |
| 2011 FY | 2.2 Million USD | 142.71% |
| 2011 Q4 | 912.73 Thousand USD | 581.95% |
| 2011 Q3 | 133.84 Thousand USD | -41.27% |
| 2011 Q2 | 227.89 Thousand USD | -75.64% |
| 2010 FY | 910.42 Thousand USD | 216.1% |
| 2010 Q1 | 66.69 Thousand USD | 14.24% |
| 2010 Q2 | 114.97 Thousand USD | 72.41% |
| 2010 Q3 | 111.65 Thousand USD | -2.89% |
| 2010 Q4 | 617.81 Thousand USD | 453.34% |
| 2009 Q2 | 73.72 Thousand USD | 37.99% |
| 2009 Q3 | 102.92 Thousand USD | 39.61% |
| 2009 Q1 | 53.42 Thousand USD | -28.48% |
| 2009 Q4 | 58.37 Thousand USD | -43.28% |
| 2009 FY | 288.02 Thousand USD | -0.75% |
| 2008 Q4 | 74.69 Thousand USD | -3.09% |
| 2008 Q2 | 75.13 Thousand USD | 18.75% |
| 2008 Q1 | 63.27 Thousand USD | -13.49% |
| 2008 FY | 290.18 Thousand USD | -53.98% |
| 2008 Q3 | 77.08 Thousand USD | 2.6% |
| 2007 Q2 | 300.1 Thousand USD | 257.52% |
| 2007 FY | 630.5 Thousand USD | 232.27% |
| 2007 Q4 | 73.14 Thousand USD | -57.8% |
| 2007 Q3 | 173.31 Thousand USD | -42.25% |
| 2007 Q1 | 83.94 Thousand USD | 48.79% |
| 2006 Q2 | 45.78 Thousand USD | -2.39% |
| 2006 Q1 | 46.9 Thousand USD | -11.06% |
| 2006 Q3 | 39.55 Thousand USD | -13.6% |
| 2006 Q4 | 56.41 Thousand USD | 42.62% |
| 2006 FY | 189.75 Thousand USD | -10.14% |
| 2005 FY | 211.16 Thousand USD | 148.38% |
| 2005 Q4 | 52.73 Thousand USD | -10.8% |
| 2005 Q2 | 40.91 Thousand USD | -27.27% |
| 2005 Q1 | 56.26 Thousand USD | 314.87% |
| 2005 Q3 | 59.11 Thousand USD | 44.48% |
| 2004 Q4 | 13.56 Thousand USD | -57.93% |
| 2004 FY | 85.01 Thousand USD | 0.0% |
| 2004 Q3 | 32.23 Thousand USD | 13.06% |
| 2004 Q2 | 28.5 Thousand USD | 166.02% |
| 2004 Q1 | 10.71 Thousand USD | 0.0% |
| 2002 Q1 | - USD | 100.0% |
| 2001 Q4 | -1.48 Million USD | -638.96% |
| 2001 Q1 | 681.94 Thousand USD | 1.27% |
| 2001 FY | 20.95 Thousand USD | -99.09% |
| 2001 Q3 | 275.49 Thousand USD | -49.78% |
| 2001 Q2 | 548.6 Thousand USD | -19.55% |
| 2000 FY | 2.3 Million USD | 2.41% |
| 2000 Q2 | 416.26 Thousand USD | -39.59% |
| 2000 Q3 | 525.98 Thousand USD | 26.36% |
| 2000 Q1 | 689.06 Thousand USD | 0.0% |
| 2000 Q4 | 673.41 Thousand USD | 28.03% |
| 1999 FY | 2.25 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 96.63 Million USD | 32.746% |
| AngioDynamics, Inc. | 303.91 Million USD | 78.616% |
| AtriCure, Inc. | 399.24 Million USD | 83.722% |
| Avinger, Inc. | 7.65 Million USD | -749.318% |
| Azenta, Inc. | 665.07 Million USD | 90.228% |
| BioLife Solutions, Inc. | 143.27 Million USD | 54.639% |
| The Cooper Companies, Inc. | 3.59 Billion USD | 98.191% |
| Daxor Corporation | 1.28 Million USD | -4975.289% |
| Ekso Bionics Holdings, Inc. | 18.27 Million USD | -255.544% |
| Femasys Inc. | 1.07 Million USD | -5962.655% |
| GlucoTrack, Inc. | - USD | -Infinity% |
| Harvard Bioscience, Inc. | 112.25 Million USD | 42.103% |
| Hologic, Inc. | 4.03 Billion USD | 98.387% |
| ICU Medical, Inc. | 2.25 Billion USD | 97.123% |
| Intuitive Surgical, Inc. | 7.12 Billion USD | 99.088% |
| KORU Medical Systems, Inc. | 28.51 Million USD | -127.893% |
| LeMaitre Vascular, Inc. | 193.48 Million USD | 66.411% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -5539.135% |
| Innovative Eyewear, Inc. | 1.15 Million USD | -5539.135% |
| Masimo Corporation | 2.04 Billion USD | 96.827% |
| Microbot Medical Inc. | - USD | -Infinity% |
| Meihua International Medical Technologies Co., Ltd. | 97.09 Million USD | 33.068% |
| Merit Medical Systems, Inc. | 1.25 Billion USD | 94.831% |
| Nephros, Inc. | 14.23 Million USD | -356.453% |
| NovoCure Limited | 509.33 Million USD | 87.24% |
| NEXGEL, Inc. | 4.08 Million USD | -1489.382% |
| NEXGEL, Inc. | 4.08 Million USD | -1489.382% |
| Singular Genomics Systems, Inc. | 2.91 Million USD | -2132.561% |
| OraSure Technologies, Inc. | 405.47 Million USD | 83.972% |
| Pro-Dex, Inc. | 53.84 Million USD | -20.7% |
| Pulse Biosciences, Inc. | - USD | -Infinity% |
| Predictive Oncology Inc. | 1.78 Million USD | -3550.924% |
| Precision Optics Corporation, Inc. | 19.1 Million USD | -240.183% |
| QuidelOrtho Corporation | 2.99 Billion USD | 97.832% |
| Repligen Corporation | 638.76 Million USD | 89.826% |
| STAAR Surgical Company | 322.41 Million USD | 79.843% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 50.22 Million USD | -29.4% |
| DENTSPLY SIRONA Inc. | 3.96 Billion USD | 98.361% |
| Jin Medical International Ltd. | 19.82 Million USD | -227.876% |